Mon Sep 23 22:30:45 UTC 2024: ## MultiPlan Stock Faces Downgrade, Analyst Cuts Price Target

**New York, NY** – MultiPlan Corporation (NYSE: MPLN) saw its price target slashed by Citigroup analysts on Monday, sending ripples through the stock market. The firm reduced its price objective from $17.20 to $10.00, indicating a potential upside of 11.73% from the company’s previous close. Citigroup maintains a “neutral” rating on the stock.

This move follows a similar downward adjustment by Piper Sandler, who reiterated a “neutral” rating and issued a $1.00 price target on August 7th, down from a previous $2.00 target.

Despite these bearish outlooks, MultiPlan’s recent earnings report surprised analysts. The company reported earnings per share (EPS) of ($0.03) for the quarter ending August 1st, exceeding the consensus estimate of ($0.04) by $0.01. While revenue fell short of expectations, coming in at $233.48 million compared to the estimated $253.59 million, the company’s performance still managed to beat analyst forecasts.

However, the analysts’ pessimism may stem from MultiPlan’s continued struggles with profitability. The company reported a negative net margin of 122.73% and a negative return on equity of 8.90% for the quarter.

Despite the stock’s recent downturn, insider buying activity remains a positive indicator. CFO Douglas Michael Garis acquired 1,150,000 shares of MultiPlan stock on August 6th, and CEO Travis Dalton purchased 500,000 shares on August 7th. This substantial insider buying suggests a belief in the company’s future prospects, even amidst the negative analyst sentiment.

MultiPlan Corporation operates in the healthcare industry, providing data analytics and technology-enabled solutions for cost management, payment, and revenue integrity. The company’s services are designed to reduce medical costs and improve efficiency within the healthcare system.

Investors will be closely watching MultiPlan’s future performance to gauge the validity of analysts’ concerns and assess the potential impact on the stock price.

Read More